# PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

VOLUME 53, 1996
SUBJECT AND AUTHOR INDEX

ELSEVIER

# PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

*Founded by* MATTHEW J. WAYNER



*US Editor-in-Chief*

GEORGE F. KOOB
Department of Neuropharmacology, CVN7
The Scripps Research Institute
10666 N. Torrey Pines Road
La Jolla, CA 92037, USA
Fax: (619) 784-1595
E-mail: gkoob@scripps.edu

*European Editor-in-Chief*

SANDRA E. FILE
Psychopharmacology Research Unit
Guy's Hospital Medical School
P.O. Box 3448
London SE1 9QH, UK
Fax: 44-171-955-4627
E-mail: pbbeuro@umds.ac.uk

**Editorial Advisory Board**

LIISA AHTEE, Helsinki, Finland
LEMBIT ALLIKMETS, Tartu, Estonia
ROBERT L. BALSTER, Richmond, VA
GIOVANNI BIGGIO, Cagliari, Italy
MIKE BRILEY, Castres, France
ALLAN C. COLLINS, Boulder, CO
DONALD V. COSCINA, Toronto, Ontario, Canada
JACQUELINE N. CRAWLEY, Bethesda, MD
ANNETTE DOMENEY, Geneva, Switzerland
ADRIAN J. DUNN, Shreveport, LA
BURR EICHELMAN, Philadelphia, PA
WILLIAM J. FREED, Washington, DC
MANUEL FREIRE-GARABAL, Santiago De Compostela, Spain
RICHARD A. GLENNON, Richmond, VA
F. G. GRAEFF, São Paulo, Brazil
M. R. C. GREENWOOD, Davis, CA
ROLAND R. GRIFFITHS, Baltimore, MD
STEPHEN G. HOLTZMAN, Atlanta, GA
AKIRA HORITA, Seattle, WA
CHRIS-ELLYN JOHANSON, Detroit, MI
HAROLD KALANT, Toronto, Ontario, Canada
G. JEAN KANT, Washington, DC
KATHLEEN M. KANTAK, Boston, MA
CONAN KORNETSKY, Boston, MA
J. DAVID LEANDER, Indianapolis, IN
EMINY H. Y. LEE, Taipei, Taiwan
ALLEN S. LEVINE, Minneapolis, MN
WILLIAM J. McBRIDE, Indianapolis, IN
DONALD E. McMILLAN, Little Rock, AR
JACK H. MENDELSON, Belmont, MA
FATHY S. MESSIHA, Grand Forks, ND
ROBERT D. MYERS, Greenville, NC
R. JOHN RODGERS, Leeds, UK
JAQUELINE SAGEN, Chicago, IL
ROSARIO SAMANIN, Milan, Italy
HERMAN H. SAMSON, Winston-Salem, NC
PAUL R. SANBERG, Tampa, FL
PHIL J. SKOLNICK, Bethesda, MD
LINDA P. SPEAR, Binghamton, NY
CLARE STANFORD, London, UK
MARIE-HÉLÈNE THIÉBOT, Paris, France
DEREK VAN DER KOOY, Toronto, Ontario, Canada
JEANNE M. WEHNER, Boulder, CO
BRUNO E. WILL, Strasbourg, France
J. C. WINTER, Buffalo, NY
ALICE M. YOUNG, Detroit, MI
IAN S. ZAGON, Hershey, PA



**PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR**

*Managing Editors:*

*In the US:*
Gery Schulteis
E-mail: gerschul@riscsm.scripps.edu

*In Europe:*
Cathy Fernandez
E-mail: pbbeuro@umds.ac.uk

*Production Editor:*
John Fotia
E-mail: J.FOTIA@ELSEVIER.COM

*Publishing and Advertising Office:*
Elsevier Science Inc., 660 White Plains Road, Tarrytown, NY 10591-5153, USA
E-mail Address: ESUK.USA@ELSEVIER.COM

*Subscription Office:*
Elsevier Science Inc., 655 Avenue of the Americas, New York, NY 10010-5017, USA

*Published Monthly*
*Annual Institutional Subscription Rate* (1996): US$1825.00. Associated Personal Subscription Rates are available on request for those whose institutions are library subscribers. Prices include postage and insurance and are subject to change without notice.

*Pharmacology Biochemistry and Behavior* is an official journal of the International Behavioral Neuroscience Society. For information about the society, please contact: Marianne Van Wagner, IBNS Central Office, Division of Life Sciences, The University of Texas at San Antonio, 6900 North Loop 1604 West, San Antonio, TX 78249-0662, USA. E-mail: EDITOFF@LONESTAR.UTSA.EDU; Fax: (210) 691-4510. Members of the International Behavioral Neuroscience Society may order personal subscriptions at a concessional rate; details of this rate are available upon request.

ELSEVIER

Pharmacology Biochemistry and Behavior, Vol. 53, No. 4, pp. I–VIII, 1996
Copyright © 1996 Elsevier Science Inc.
Printed in the USA. All rights reserved
0091-3057/96 $15.00 + .00

# SUBJECT INDEX

Abecarnil, 87, 1005
Aberrant drinking, 33
Absence, 73
Acetylcholine, 179, 679, 783, 809
ACTH, 517, 641, 965
ACTH analog, 163
Activity, 303, 701
Addiction, 11, 433, 791, 809
Adenosine $A_1$ receptors, 341
Adjunctive behavior, 123
Adrenal weight, 965
Aging, 641
Agonists, 995
*Agouti*, 425
Aggression, 329
Aggressive behavior, 951
Alcohol, 585
Alcohol aversion, 487
Alcohol intake, 891
Alcohol-nonpreferring rats, 487, 585
Alcohol-preferring rats, 487, 585
Alcohol reinforcement, 487
Alcohol sensitivity, 585, 723
Alcohol tolerance, 585
α-Methyl-*p*-tyrosine, 379
αMPT, 1
$\alpha_1$-Adrenoceptors, 1017
$\alpha_2$-Adrenoceptors, 291, 1017
Alphaxalone, 777
Allopregnanolone, 777
Amino acids, 549
Amnesia, 391
Amphetamine, 511, 695, 741, 817, 833
Anabolic-androgenic steroids, 329
Analgesia, 133, 567, 665, 927, 943
Androgen, 741
Androgen-dependent behavior, 213
Animal model, 11, 123
Aniracetam, 277, 943
Anorexant khat, 297
Anorexia, 839
Anorexia nervosa, 123, 433
Antagonists, 995
Antianxiety, 493
Anticonvulsant, 87
Anticonvulsant drugs, 559
Antinociception, 205, 411, 449, 567, 943
Antipsychotic, 493
Anxiety, 271, 369, 541, 825, 1005
Anxiogenic drugs, 271
Anxiolysis, 87
Anxiolytics, 271, 369, 753, 825
$A_1$ receptors, 249
Apomorphine, 335, 417, 817, 833
Aprophen, 463
Arecoline, 713
Associative learning, 649
Atropine, 463
Attention, 163, 213, 617
Atypical opioid systems, 433
Audiogenic-like seizures, 503
Audiogenic seizures, 503
Auto-addiction, 433
Aversion, 511
($A^{vy}$), 425

Baclofen, 73, 303
Barakol, 753
Behavior, 493, 995
Behavior genetics, 623
Benactyzine, 463
Benzodiazepine, 1, 87, 593, 1005
Benzodiazepine receptors, 581, 723
Benzoylecgonine, 133
β-Adrenoceptor antagonists, 903
β-Adrenoceptors, 1017
β-Endorphin, 425
β-FNA, 927
Bicuculline, 629, 673
Black bear, 885
Blink reflex, 857
Body temperature, 657
Body weight, 657
Brain, 205, 843
Brain angiotensin, 687
Brain cholinergic systems, 687
Brain damage, 163
Brain injury, 679
Brain monoamines, 469
Brain phospholipid, 843
Brain serotonergic systems, 687
Branched-chain amino acids, 449
Bretazenil, 723
Bromocriptine, 833
Burimamide, 567

Cadmium, 687
Cadmium intoxication, 687
Cadmium neurotoxicity, 687
Calcium-calmodulin protein kinase activity, 155
Calorimetry, 549
Cannabinoid, 657
Cannabis, 657
Carbamazepine, 243, 559
Carbon monoxide, 355
Cardiovascular, 927
Cardiovascular responses, 927
*Cassia siamea*, 753
Catalepsy, 437
Catecholamines, 141, 213
CCK, 493
CCPA, 249
Central administration, 665
Cerebellum, 147
CGP 35348, 943
CGS8216, 87
Chicken embryo, 603
Chlordiazepoxide, 593
Chlorpromazine, 115
Choline, 783
Cholinergic activity, 613
Cholinergic antagonist, 463
Cholinergic neurochemistry, 771
Cholinergic pathways, 735
Cholinergic stimulation, 1017
Cholinergic system, 713
Cholinesterase inhibition, 771
Chronic administration, 935
Chronic ethanol, 249
Chronic methamphetamine, 437
Chronic stress, 517
Cigarettes, 355
Cingulate cortex, 617
Circadian, 843
Circadian rhythm, 141
Circadian wheel-running activity, 843
Citalopram, 825
Classical conditioning, 147
Clonidine, 1, 291, 979
$CO_2$, 205
Cocaethylene, 133
Cocaine, 5, 57, 185, 191, 133, 227, 243, 525, 623, 695, 747, 863, 911, 919
Conditioned fear stress, 825
Conditioned place preference, 99, 185, 191, 531, 657
Conditioned taste aversion, 243, 657, 891
Conditioned taste avoidance, 657
Conflict behavior, 369
Conflict responding, 593
Continuous drug infusion, 713
Convulsions, 493
Corticosterone, 641
CP 55,940, 657
CPP, 799
Crab, 441
Crack, 57
Cromakalim, 839
Cue learning, 303
Cyproheptadine, 441

*d*-Amphetamine, 297
DA $D_3$ receptors, 525
DAMPGO, 927
Daytime activity, 265
Defensive reflex, 857
Dehydroepiandrosterone, 51

*d*-Fenfluramine, 641
δ-Opioid receptor, 477
δ-Receptor, 665
Dependence, 11, 791
Depression, 535
Development, 41, 425, 603
Dexfenfluramine, 549
D-Fenfluramine, 155
Diazepam, 115, 271, 317, 753, 1005
Diestrus-2, 965
Dizocilipine, 701
D-Norfenfluramine, 155
DOI, 603
Dominance, 285
Dominance rank, 11
$D_1$ receptors, 481, 759
DOPAC, 41, 575
Dopamine, 41, 99, 179, 221, 257, 285, 417, 455, 493, 575, 641, 695, 863
Dopamine agonists, 481, 759
Dopamine antagonists, 481, 759
Dopamine (DA), 425
Dopamine $D_1$ receptors, 935
Dopamine $D_2$/$D_3$ receptors, 935
Dopamine neurotransmission, 107
Dopamine receptor supersensitivity, 185
Dopamine release, 155
Dopaminergic stimulation, 1017
Dothiepin, 265
DPDPE, 885
[D-Pen$^2$]-enkephalin, 877
[D-Pen$^2$]-enkephalin, 877
Drinking, 347
Drinking behavior, 687
Drug abuse, 657, 871
Drug aerosols, 57
Drug discrimination, 107, 455, 891, 979
Drug reinforcement, 477
Drug reward, 511
Drugs of abuse, 243, 617
DSP-4, 213, 391
$D_3$ Receptor, 695
$D_2$ dopamine receptors, 291
$D_2$ Receptor, 695, 759
Duration, 965
Dynorphin A, 885

Eating disorders, 433
Ecgonine, 133
Ecgonine methyl ester, 133
EEG, 73
8-OH-DPAT, 323, 385
Ejaculation, 329
Electrophysiology, 493
Elevated plus-maze, 271, 753
Elicited PGO waves, 323
Endogenous opioid peptides, 81
Endogenous opioids, 613
Energy metabolism, 549
Environment-specific sensitization, 899
Epilepsy, 73
Essential, 843
Essential fatty acids, 843
Estrogen, 27
Ethanol, 11, 51, 891, 919, 971
Ethanol alcohol preference, 33
Ether stress, 965
Eticlopride, 759
Etonitazene, 11, 871
Evoked potentials, 817
Exploratory head dipping, 877
Ex vivo binding, 41

Fear, 649
Feeding, 1005
Felbamate, 559
Female, 433
Female F-344 rat, 641
Fenfluramine, 99, 511
FG5865 Fimbria lesion, 163
5β-Pregnanediol, 777
5-HIAA, 965
5-HT (5-hydroxytryptamine, serotonin), 995
5-HT receptors, 107
$5\text{-HT}_{1A}$ receptor, 385, 825
$5\text{-HT}_{1b}$ receptors, 257
$5\text{-HT}_{1B/D}$, 535
$5\text{-HT}_3$ receptors, 271, 765
$5\text{-HT}_{2C}$ receptor, 107, 385
5-Hydroxytryptamine, 33, 1023
5,7-DHT, 951
Fixed-ratio schedule, 979
Flunarizine, 155
Fluvoxamine, 265
Food, 995
Food competition, 951
Food intake, 221, 297, 425, 433, 777, 839, 1023
Food-related drinking, 347
Food restriction, 995
Food reward, 221
Foot-shock, 735
Forced, 843
Forced swimming, 469
Forced swimming test, 843
Formalin, 411
Fowls, 995
Free fatty acids, 549
Freezing behavior, 825
Functional recovery, 163

GABA, 27, 51, 629, 943, 995
GABA (γ-aminobutyric acid), 995
$GABA_A$, 971
$GABA_A$ receptors, 361
$GABA_A$ receptor subtypes, 723
$GABA_B$, 73, 303
$GABA_B$ receptor, 943
$GABA_2$ receptor, 777
γ-Butyrolactone, 73
γ-Hydroxybutyric acid, 73
γ-Linolenic, 843
γ-Linolenic acid, 843
Gastric emptying, 839
Gastric lesion, 957
GBR12909, 911
Generalization, 891
Genetics, 425, 585, 871
Ginger, 271
*Ginkgo biloba*, 271
Glucose, 549
Glycine, 791
Glycogen, 549
Gnawing behavior, 67
GR 127935, 535
Grooming, 935
Guinea pig, 799
Guinea pig ileum, 885

Habituation, 401, 517, 857
HAD rats, 33
Halcion, 317
Haloperidol, 401, 437, 833, 853
Handling for vaginal smear screening, 965

Hibernation, 885
Hibernation-induction trigger, 885
High responder, 191
Hippocampus, 361, 613, 899
Histamine, 347
Histamine $H_1$-receptor antagonist, 567
Histamine $H_2$-receptor antagonist, 567
Histamine $H_2$-receptor agonist, 567
Histamine $H_2$-receptor antagonist, 567
Histaminergic, 347
$H_1$ receptors, 347
Horizontal activity, 877
Hormone, 27
Hot-plate analgesia test, 449
HPNS, 257
$H_3$ receptors, 347
$H_2$ receptors, 347
Hyperactivity, 185
Hyperphagia, 87, 1005
Hypoalgesia, 649
Hypothalamic 5-HT, 965
Hypothalamus, 425
Hypothermia, 87, 657

Ibogaine, 863
Immunity, 227
Impromidine, 567
Individual differences, 191, 511
Indole levels and release, 155
Inferior colliculus lesions, 503
Inferior colliculus nuclei, 503
Infusion, 309
Ingestion, 731
Ingestive behavior, 657
Insulin, 549
Intracerebral injection, 541
Intracranial self-stimulation, 741
Intrauterine cocaine, 857
Intravenous, 309
In vitro binding, 41
In vivo microdialysis in freely moving rats, 99
Ipsapirone, 825, 891
Isolation, 41
Isradipine, 243
IV, 919

Juvenile rats, 987

κ-Agonists, 411
κ-Opioid, 863
κ-Receptor, 665
$K^+$ channel opener, 839

Lamotrigine, 559
Lapping, 853
Lateral hypothalamus, 417
Laterodorsal tegmental nucleus, 323
Learning, 317, 385, 765
Learning/memory, 735, 943
Licking, 853
Lithium, 511
Locomotion, 335, 935
Locomotor activity, 87, 191, 257, 481, 535, 623
Long-term facilitation, 735
Loreclezole, 723
Loss of control, 11
Low responder, 191
Lymphocyte, 227
LY262691, 493

Majonoside-R2, 957
Male, 433
Maze, 463
Maze-learning selected chicks, 581
Mazindol, 911
MBDB, 99
mCPP, 107
MDMA, 99, 455, 477
Medial frontal cortex, 641
Medial prefrontal cortex, 5
Memantine, 791
Membrane, 27
Memory, 51, 317, 361, 385
Memory and learning, 713
Menthol, 355
Metergoline, 1023
Methamphetamine, 575
Methiothepin, 155
Methylecgonidine, 57
Methylnaloxonium, 809
Mice, 285, 329, 411, 425, 433, 437, 701, 735, 843
Microdialysis, 221, 575, 679, 747, 809
Microwaves, 613
Midazolam, 649
(−) Eticlopride, 525
(−)-Norpseudoephedrine, 297
(−)-3-PPP, 903
MK-801, 369, 701
MMAI, 99
Moclobemide, 469
Morphine, 227, 411, 433, 511, 531, 731, 791, 809, 979, 1013
Morphine derivatives, 665
Morris maze, 163
Morris water maze, 303, 783
Motility, 525
Motivation, 115
Motor, 179
Mouse, 673, 877
Mouse spleen, 141
MSG, 425
Mu-opioid, 927
μ-Receptor, 665
Muscimol, 629, 971

Naloxone, 81, 411, 885
Naltrexone, 987
Naltrindole, 477
Neonatal exposure, 197
Neuroactive steroid, 27
Neuroactive steroids, 777
Neurosteroids, 27, 51
Nicotinamide, 783
Nicotine, 81, 309, 355
Nicotine abstinence, 81
Nicotine dependence, 81
Nicotine withdrawal, 81, 635
Nictitating membrane, 617, 857
Nitric oxide, 147, 673, 1013
NMDA antagonists, 799
NMDA receptor antagonists, 701, 791
NMDA receptors, 799
*N*-Methyl-DL-aspartate, 673
$N^6$-*p*-Sulfophenyladenosine (*p*-SPA), 341
Nociception, 27, 133
Nω-Nitro-L-arginine, 673
Nongenomic, 27
Nootropic, 943
Noradrenaline, 285, 541
Noradrenergic, 979
Noradrenergic activity, 517
Nor-binaltorphimine, 411
Norcocaine, 133
Norepinephrine, 141, 213, 235, 641, 1023
Novelty, 191
NPC 17742, 791
NS-3 (CG3703), 391
Nucleus accumbens, 99, 221, 635, 747, 809
Nucleus basalis, 277
Nucleus basalis magnocellularis (NBM), 391

Obesity, 425, 549
Object recognition, 277
Obsessive-compulsive disorder, 123
Ontogeny, 575
OPC-14597, 903
Open field, 303
Open-field test, 833
Operant response, 335
Operant test battery, 115
Opiate antagonists, 81, 987
Opiates, 11, 81, 809, 871
Opioids, 67, 433, 871, 885, 987
Oral, 919, 995
Oral movements, 935
Organophosphate, 771
ORG2766, 163
Osmotic minipumps, 713

Pain, 411, 449, 567
Palatability, 221, 731
Panax ginseng, 185
Paradoxical sleep, 291
Paraventricular nucleus, 1023
Parental behavior, 987
Parkinsonian bradykinesia, 335
Parkinsonism, 179
Partial agonists, 87
Particle-size aerosol, 57
Passive avoidance, 735
Passive avoidance response, 391
Pavlovian conditioning, 617
Peak force, 853
Peak procedure, 759
Pedunculopontine tegmental nucleus, 323
Penile erection, 525
Pentobarbital-induced sleep, 957
Pentylenetetrazole, 73, 673
Performance, 317
Peripheral chemoreceptors, 341
Petit mal, 73
PGO waves, 323
Phaclofen, 73
Phenobarbital, 369, 559
PI turnover, 107
Picrotoxin, 673
Piracetam, 943
Place aversion, 99
Place conditioning, 487, 511
Place preference, 511, 1013
Plaque-forming cell response, 235
Plasma, 927
Plasticity, 147
(+)-Amphetamine, 455
(+)-Fenfluramine, 455
(+)MK-801, 799
(±)Cyanopindolol, 257
Plus-maze, 1005
Polydrug exposure, 197
Postictal prolactin, 503
Prazosin, 979
Prefrontal cortex, 809
Pregnenolone, 51, 777
Pregnenolone sulfate, 51
Prenatal, 843
Prenatal alcohol effects, 197
Prenatal cocaine, 617, 857
Prenatal cocaine effects, 197
Prenatal ethanol intoxication, 361
Prepubertal, 987
Pressure, 257
Problem solving, 197
Progestin, 27
Progressive ratio, 5, 115
Prolactin, 379, 641
Propranolol, 979
pseudo-Parkinsonism, 853
Psychological stress, 957
Psychomotor performance, 265
Purposeless chewing, 179
Pyruvate kinase, 549

Quinpirole, 379, 759

Rabbit, 857
(R)-α-methylhistamine, 567
Race, 355
Rat pup, 41
Rats, 1, 11, 73, 205, 249, 271, 291, 335, 341, 379, 385, 391, 433, 455, 463, 531, 559, 593, 657, 679, 765, 809, 853, 871, 891, 919, 971, 979, 1013
Rearing, 877
Receptor, 995
Reference memory, 463
Reflex modification, 857
Reinforcement, 5, 243, 657, 971
Repeated prenatal exposure, 771
Repeated testing procedures, 369
Resistance, 965
Response decrements, 853
Response sequence, 335
Restraint, 205, 927
Retrograde messenger, 147
Reward, 99, 191, 417, 657, 695, 731
Ritanserin, 603
RO 41-9067, 291
Ro16-6028, 87
Ro23-1590, 87
Ro23-0364, 87
Rotation, 903
RTI-55, 911
RU 24969, 535
Running wheel activity, 329

Saccharin, 919
Saccharin taste aversion, 695
Saclofen, 73
Salbutamol, 979
Schizophrenia, 493
SCH23390, 437, 759
Scopolamine, 277, 463, 679, 713, 735, 853
Seizure, 73
Selected rat lines, 723
Selective breeding, 871
Self-administration, 5, 919, 971
Self-stimulation, 417
Sensitization, 441, 585, 623, 911, 935
Sensorimotor, 701
Sensorimotor integration, 857
Sensory gating, 817
Septal area, 541
Serotonin, 123, 257, 271, 323, 455, 441, 549, 641, 765, 747, 825, 863, 891

Serotonin agonists, 385
Serotoninergic activity, 517
Serotonin (5-HT), 425
Serotonin receptors, 33
Serotonin reuptake inhibitor, 123
Serotonin$_2$ receptors, 603
7-Hydroxy-*N*,*N*-di-*n*-propyl-2-aminotetralin, 695
7-OH-DPAT, 379, 695
17$\beta$-Estradiol, 379
Sex, 433
Sexual behavior, 329, 525
Sigma receptor, 695
6-Hydroxydopamine, 5, 817
SKF 38393, 759
Sleep, 1
Sleep apneas, 341
Sleep-wake cycle, 559
Smoking, 309
Social behavior, 11
Social isolation, 11, 531
Spatial learning, 303, 361
Spatial learning and memory, 701
Spatial working memory, 541
SRBC, 235
Stereotyped behavior, 525
Stereotypy, 903, 935
Steroid mechanism, 27
Stimulants, 481
Stone maze, 713
Stress, 41, 123, 205, 235, 641, 735
Stress model, 469
Stress susceptibility, 581
Striatum, 179, 257, 575, 635
Strong learning, 629
Subdiaphragmatic vagotomy, 839
Substantia nigra, 493
Substantia nigra lesions, 503
Sucrose, 731, 971
Sweet solution consumption, 243

Tail-flick latency, 27
Tail-flick test, 665
Taste, 731
Taste aversion, 511, 839
Taste avoidance, 511
Taste reactivity, 731
Temporal response differentiation, 115
TFMPP
Thigmotaxia, 303
Time course, 369, 935
Time estimation, 115, 759
Tolerance, 227, 593
Tongue, 853
Tongue protrusions, 935
Topography, 355
Tremor, 179
Triazolam, 317
Trifluperazine, 155
Trihexyphenidyl, 463
Tropane, 133
Turnover, 41
(2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxamide), 33
Type A monoamine oxidase inhibitor, 469

U-50488H, 411
U78875, 87
Uncontrollable foot-shock, 877
Undernourished pigeon, 951

Vacuous chewing, 179
Vacuous chewing movements, 401
Valium, 317
Vapor pressure, 57
Ventral tegmental area (VTA), 971
Ventral tegmentum, 493
Viable yellow, 425
Vietnamese ginseng extract, 957
Vietnamese ginseng total saponin, 957
Vocal control system, 213
Voltammetry, 257

Water intake, 297
Water maze, 317, 385
Weak learning, 629
Withdrawal, 249, 593, 791, 809
Women, 355
Working memory, 277, 463

Yawning, 903, 1017
Yohimbine, 979

ZG-63, 723
Zolpidem, 723

**VOLUME 53 1996**

## AUTHOR INDEX


Abraini, J. H., 257
Adami, M., 559
Aggio, J., 441
Ahijevych, K., 355
Akiyama, K., 575
Ali, S. F., 425
Allen, J. D., 759
Allen, M. T., 147
Altemus, M., 123
Amendola, C. A., 477
Anderson, T. M., 635
Anelli, M., 155
Anisman, H., 235
Antunes-Rodrigues, J., 503
Arce, A., 581
Armario, A., 517
Arolfo, M. P., 361
Ashford, J., 265
Askanazi, J., 449

Badiani, A., 899
Bailey, E. C., 885
Baker, G., 5
Baker, L. E., 455
Balcaen, P., 843
Bao, J., 679
Baptista, T., 747
Barclay, S. R., 213
Bardo, M. T., 695
Barnes, C., 433
Barron, S., 197
Bartolini, A., 567, 943
Bartolini, L., 277
Baskin, P., 179
Battles, A. H., 205
Bayer, B. M., 227
Behm, F. M., 309
Belotti, M., 541
Bennett, G. W., 753
Berger, J. E., 493
Berra, B., 603
Bertorelli, R., 559
Bevins, R. A., 695
Biggio, G., 249
Björk, A., 33
Boschmann, M., 549
Bourne, R. C., 629
Bourson, A., 107
Boyd, E. A., 753
Bratt, A. M., 713
Braun, C. J., 347
Brener, J. M., 335
Bridges, R. S., 987
Brioni, J. D., 361
Brockington, A., 911
Bronson, F. H., 329
Brosnan-Watters, G., 701
Browman, K. E., 899
Bruce, D. S., 885
Bulcão, C., 687
Butterfield, D. A., 665

Caccia, S., 155
Campbell, D. B., 641
Campmany, L., 517
Caputo, F. A., 425
Carino, M. A., 613
Carley, D. W., 341
Carlson, K. R., 871
Carrol, F. I., 911
Carroll, M. E., 919
Carter, V. A., 81
Casamenti, F., 277
Chanda, S. M., 771
Chappelle, A. M., 972
Chen, H. A., 87
Chen, S.-W., 87, 777
Cho, D.-H., 185
Cinquanta, M., 155
Clark, A. S., 741
Clash, K., 41
Clelford, J., 235
Clements, M. P., 629
Commissaris, R. L., 369
Concas, A., 249
Conceição, I. M., 833
Cook, D. F., 243
Coscina, D. V., 1023
Costall, B., 713
Crespi, D., 155
Crooks, P. A., 665
Cuccheddu, T., 249
Cunha, M., 687
Cunningham, S. J., 81
Currie, P. J., 1023
Czachura, J. F., 493

D'Amico-Rasmussen, Q., 433
Darlington, C. L., 799
Das, S., 853
Davenport, K. E., 927
Davies, M. F., 87, 777
Deachapunya, C., 753
De Beun, R., 891
De Castro E Silva, E., 687
De Oliveira, I., 687
de Saint Hilaire, Z., 1, 291
De Souza Silva, M. A., 271
De Vry, J., 891
Del Prete, E., 839
Delzer, T. A., 695
Demirci, M., 355
Ding, X. Z., 227
Dixon, C. E., 679
Domae, M., 379
Domeney, A. M., 713
Doretto, M. C., 503
Drummond, L., 235
Duc, N. M., 957
Duncan, J. E., 27
Dykstra, L. A., 979

Egan, M. F., 401
Ellison, T., 481
Elmer, G. I., 623, 911
Endo, T., 673

Fachinelli, C., 951
Fairweather, D. B., 265
Fang, C. P., 57
Fantino, M., 221
Felten, D. L., 141
Felten, S. Y., 141
Ferguson, J., 401
Ferguson, S. A., 115
Fernández, A. G., 535
Ferrari, F., 525
Ferreira, H., 687
Ferri, N., 559
Fink, H., 1005
Finkell, J., 347
Fishkin, M. D., 477
Floris, S., 249
Fowler, S. C., 853
Fraioli, S., 297
Frederick, D. L., 759
Fregoneze, J. B., 687
Frenz, U., 549
Frisch, Ch., 271
Frittoli, E., 155
Froehlich, J. C., 585
Frussa-Filho, R., 833
Frye, C. A., 27
Fujikawa, M., 903
Fulginiti, S., 361
Fung, Y. K., 635
Furukawa, T., 379, 903, 1017

Gahtan, E., 919
Gaillard, J. M., 1, 291
Galanopoulou, P., 965
Galeotti, N., 943
Galey, D., 541
Galliven, E., 123
Garcia-Cairasco, N., 503
George, M., 641
Ghelardini, C., 567, 943
Ghosh, S., 317
Gibbons, C. H., 741
Gillespie, J., 355
Giorcelli, P., 155
Gispen, H. W., 163
Giuliani, D., 525
Glowa, J. R., 123
Gobbi, M., 155
Goldberg, S. R., 623, 911
Gong, W., 191
Gordon, B. H., 641
Gorelick, D. A., 623, 911
Graefe, J. F., 57
Grauer, E., 463
Grota, L. J., 141
Grouhel, A., 411
Guy, A. W., 613

Habash, T., 979
Häcker, R., 271
Hall, F. S., 417
Hammond, J., 843
Handa, R. J., 641
Hansen-Trench, L., 197
Hara, S., 673
Haraguchi, M., 972
Harding, C. F., 213
Harvey, J. A., 617, 857
Hasenöhrl, R. U., 271
Hashim, A., 863
Hayes, R. L., 679
Hellgren, E. C., 885
Helton, D. R., 493
Hernandez, L., 747
Hernandez, M. C., 227
Heyne, A., 11
Hindmarch, I., 265
Hodge, C. W., 971
Hoebel, B. G., 747, 809
Hong, E., 765
Horita, A., 613
Horton, N. D., 885
Houdi, A. A., 665, 927
Hough, L. B., 205
Huang, Y.-S., 843
Hubbell, C. L., 477
Hughes, C. E., 979
Huong, N. T. T., 957
Huston, J. P., 271
Hyde, T. M., 401

Inoue, T., 379, 825, 903
Ison, M., 951
Issakidis, C. N., 657
Itoh, Y., 391
Iwata, N., 673

Jacobson, D., 885
Jagadeesh, J., 355
Jang, C.-G., 185
Jerram, A. H., 799
Jodar, L., 735
Johnson, R. G., 817
Johnston, R. E., 649
Josephy, M., 163

J. Sleight, A., 107
Justice, JR, J. B., 191

Kaiser, D. H., 197
Kallman, M. J., 493
Kalmus, G. W., 33
Kaneto, H., 735
Kang, S.-Y., 185
Kano, S., 673
Kant, G. J., 317, 385
Kapon, J., 463
Katz, D. P., 449
Keefe, M. E., 347
Kehoe, P., 41
Kelley, S. P., 141
Kelly, M. E., 713
Kerr, L., 235
Kim, H.-S., 185
Kim, Y.-M., 347
Kimura, H., 1017
Kimura, K., 391
Kivastik, T., 1013
Klein, J., 783
Konstandi, M., 965
Köppen, A., 783
Kornetsky, C., 67
Korpi, E. R., 723
Kostal, L., 995
Kottayil, S., 665
Koyama, T., 825
Kraly, F. S., 347
Kriem, B., 257
Kurashima, M., 379
Kuriiwa, F., 673
Kuroda, S., 575
Kurtz, D. L., 585

Labounty, L. P., 919
Lai, H., 613
Lajtha, A., 863
Lake, R. J., 81
Lamberti, C., 567
Lau, Y.-S., 635
Lawhorn, J., 433
Leong, Y., 123
Lévesque, S., 843
Li, T.-K., 487, 585
Li, X., 575
Lindenfeld, R. C., 741
Lindqvist, E., 817
Liu, X., 335
Loew, G. H., 87, 777
Löffelholz, K., 783
Lohmann, A., 891
Long, D. A., 679
Long, T. A., 33
Lorens, S. A., 641
Lucki, I., 593, 935
Lumeng, L., 487
Luthman, J., 817
Lutz, T. A., 839

McBride, W. J., 487
McCutcheon, D., 843
McGonigle, P., 935
McGregor, A., 5
McGregor, I. S., 657
McNamara, R. K., 303
McQuarters, A., 433
Madden, J. A., 133
Madden, K. S., 141
Makhay, M. M., 455
Maldonado, H., 441
Malin, D. H., 81
Malmberg-Aiello, P., 567
Mann, P. E., 987
Manner, T., 449
Marín, R. H., 581
Mark, G. P., 809
Markovska, V. L., 369
Marona-Lewicka, D., 99
Marrazzi, M. A., 433
Marsden, A. C., 753
Marsden, C. A., 531
Marson, L., 927
Martel, B., 221
Mascia, M. P., 249
Matecka, D., 723, 911
Matsumoto, K., 957
Mattern, C. M., 271
Mattingly, B. A., 481
Maughan, K. R., 385
Meininger, G. R., 385
Melchior, C. L., 51
Mendella, P. D., 877
Meneses, A., 765
Mennini, T., 155
Miles, C., 511
Minetti, A., 361
Mischler, S. A., 205
Miura, H., 469
Mizuki, Y., 437
Monti, D., 341
Moolten, M. S., 871
Morrison, A. R., 323
Mostallino, M. C., 249
Mukai, T., 673
Murphy, C. M., 549
Murphy, D. L., 123
Murphy, J. M., 487
Murzi, E., 747
Mutsaers, L., 843
Myers, R. D., 33

Nagashima, M., 379, 903, 1017
Nagatsu, T., 469
Nakahara, D., 469
Naoi, M., 469
Nardi, A., 701
Naumenko, E. V., 285
Naylor, R. J., 713
Neely, T. M., 385
Neill, D. B., 191
Neisewander, J. I., 935
Nencini, P., 297
Nham, N. T., 957
Nichau, Ch., 271
Nichols, D. E., 99
Ninichuk, P. J., 369
Noack, R., 549
Nonaka, K. O., 503

Oeltgen, P. R., 885
Ogasawara, T., 391
Oh, K.-W., 185
Ohta, T., 469
Okimoto, L., 987
Olney, J. W., 701
O'Neill, M. F., 535
Ongini, E., 559

Palacios, J. M., 535
Parker, L. A., 511, 731
Paule, M. G., 115
Payne, M. C., 81
Pepeu, G., 277
Perra, C., 249
Perrella, D., 297
Petit, N., 107
Picker, M. J., 979
Pizzi, W. J., 243
Pol, O., 517
Pollock, J., 67
Pongsakorn, S., 753
Pope, C. N., 771
Popik, P., 791
Powers, R. H., 133
Prior, G., 657
Python, A., 291

Rada, P. V., 809
Radulovacki, M., 341
Rakitin, A., 441
Ramalho, M. J., 503
Rase, K., 481
Rasmussen, K., 493
Reid, L. D., 477
Rex, A., 1005
Rhee, G.-S., 99
Rheu, H.-M., 185
Rice, J., 133
Rice, K. C., 911
Rideout, H. J., 731
Ritzmann, R. F., 51
Rizzo, A., 603
Roberts, D. C. S., 5
Robinson, T. E., 899
Robinson, III, T. N., 385
Rodríguez Echandía, E. L., 951
Rodriguez, L., 777
Romano, A. G., 617, 857
Rose, G. M., 817
Rose, J. E., 309
Ross, R. J., 323
Rostain, J.-C., 257
Rothman, R. B., 623, 911
Rowlett, J. K., 481
Rudler, A., 107
Rutkauskaite, J., 1013

Sakai, K., 575
Salamone, J. D., 179
Samson, H. H., 972
Sanford, L. D., 323
Sarmento, C., 687
Sarviharju, M., 723
Satta, S., 249
Saulnier-Dyer, C. M., 871
Savory, C. J., 995
Scallet, A. C., 425
Scharrer, E., 839
Schmid, M. J., 635
Schmidt, B. H., 783
Schneider, R., 891
Schuelke, G. S., 133
Segar, T. M., 197
Seong, Y.-H., 185
Serova, L. I., 285
Sershen, H., 863
Setran, D. P., 885
Sfikakis, A., 965
Shirakawa, K., 379
Shoemaker, W. J., 41
Shojaie, J., 57
Short, P. E., 81
Shumsky, J. S., 593
Siegel, S., 511
Skelton, R. W., 303
Skipsey, K., 41
Skolnick, P., 791
Smith, P. F., 799
Sparber, S. B., 603
Sprague, J. E., 99
Spruijt, M. B., 163
Steinmetz, J. E., 147
Stellar, J. R., 417
Stephens, D. N., 1005
Stevens, K. E., 817
Stewart, R. B., 487, 585
Strecker, R. E., 335

Takahashi, M., 735
Tamura, M., 391
Taylor, K. M., 809
Tejani-Butt, S. M., 323
Teneud, L. M., 747
Terry, L. C., 133
Thongsaard, W., 753
Toropainen, M., 723
Tramell, M. S., 885
Tribuzio, R. A., 347
Trivedi, A., 987
Tsai, J., 477
Tsakayannis, D., 965
Tsuchida, K., 575
Tsuchiya, K., 825
Turenne, S. D., 511

Ujike, H., 575
Ukai, Y., 391
Ushijima, I., 437

VAN DER Staay, F.-J., 783
Van Doremalen, E., 163
VAN Loon, G. R., 927
Van Rijzingen, I. M. S., 163
Vasilakis, A. A., 317
Virgolini, M. B., 361

Wainwright, P. E., 843
Wanner, D., 107
Watanabe, H., 957
Waterman, S. A., 213
Westman, E. C., 309
Wettstein, J. G., 411
Wilson, O. B., 81
Wolff, G. L., 425
Wong, G., 723
Wongwitdecha, N., 531
Wood, R. W., 57
Wozniak, D. F., 701
Wright, W. L., 385
Wyler, R., 107
Wylie, R. M., 317
Wyvell, C., 919

Xie, Z., 369

Yamada, K., 379, 903, 1017
Yamada, M., 437
Yamasaki, K., 957
Yoshikuni, Y., 391

Zacharko, R. M., 877
Zaharia, M., 235
Zaias, J., 987
Zharkovsky, A., 1013
Zweifel, M., 585
Zwingelstein, C., 107